Press release
-
Press Release
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV…
Read More » -
Business Wire2 weeks ago
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure…
Read More » -
Business Wire2 weeks ago
Debevoise Secures Second Circuit Affirmance of Dismissal of $16 billion Claim Against YPF S.A.
NEW YORK–(BUSINESS WIRE)–Debevoise & Plimpton LLP has secured affirmance from the U.S. Court of Appeals for the Second Circuit of…
Read More » -
Business Wire2 weeks ago
YRD Investors Have Opportunity to Join Yiren Digital Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$YRD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire2 weeks ago
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PODD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire2 weeks ago
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire2 weeks ago
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire2 weeks ago
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More » -
Business Wire2 weeks ago
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More » -
Business Wire2 weeks ago
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with…
Read More »
